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Nseir and colleagues presented data from a large
multicenter study of patients with ventilator-associated
tracheobronchitis (VAT), demonstrating that
appropriate antibiotic therapy for VAT was an
independent predictor for reducing transition to
pneumonia (ventilator-associated pneumonia, or
VAP). These data added to the growing evidence
supporting the use of appropriate antibiotic therapy
for VAT as a standard of care to prevent VAP and
improve patient outcomes.Bouza and colleagues [8] compared use of pre-emptive
antibiotic therapy versus controls to prevent VAT andIntroduction
In a previous issue of Critical Care, Nseir and colleagues
[1] presented interesting data demonstrating that appropri-
ate antibiotic therapy for ventilator-associated tracheobron-
chitis (VAT) reduced transition to ventilator-associated
pneumonia (VAP). Of the 122 study patients, 8.1% de-
veloped VAT, of whom 13.9% later developed VAP.
Pseudomonas aeruginosa, Staphylococcus aureus, and
Acinetobacter baumannii were the most common path-
ogens isolated. In the multivariable analysis, appropriate
antibiotic therapy was the only risk factor independently as-
sociated with reduced risk of transition to VAP (P =0.009).
Previous studies have demonstrated that patients diag-
nosed with VAT or VAP (or both) have increased venti-
lator days, length of ICU stay, and associated health-care
costs [2-6]. Patients with VAT or VAP present with ele-
vated temperature, leukocytosis, purulent sputum with* Correspondence: donald.e.craven@lahey.org
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publicdomain/zero/1.0/) applies to the data madmany polymorphonuclear leukocytes on Gram stain,
plus an endotracheal aspirate (ETA) culture having >10
moderate (+++) semi-quantitative growth, or a quantita-
tive culture having at least 100,000 (at least 105) organ-
isms per milliliter of a bacterial pathogen [5,7]. However,
VAP also requires a new and persistent infiltrate on
chest x-ray. The fact that 10% to 30% of patients with
VAT progress to VAP makes VAT an ideal target for
antibiotic therapy to prevent VAP and improve patient
outcomes [5,7,8]. Intravenous or aerosolized antibiotic
therapy (or both) for VAT has been shown to reduce
VAP, ventilator days, and length of ICU stay [3,4,9,10].
VAP in high-risk patients following major heart surgery.
Forty patients were randomly assigned to a 3-day course
of linezolid and meropenem versus 38 control patients
followed for development of VAT, VAP or both. The
antibiotic-treated group had significantly lower rates of
VAT/VAP, 32/1,000 days versus controls 65/1,000 days
(P <0.03), and a longer time to the first episode of VAT/
VAP (9 versus 4.5 days, P =0.02).
Recently, there has been increased interest in the use of
adjunctive aerosolized antibiotic therapy for VAT and VAP,
administered by an improved nebulizer delivery system to
increase weaning from the ventilator and shorten ICU stay
[4,9,10]. A double-blind, placebo-controlled study is in pro-
gress to evaluate adjunctive aerosolized amikacin and
fosfomycin therapy for the treatment of VAP due to
Gram-negative bacilli and to decrease ventilator days
and ICU stay [11].
Interestingly, different approaches exist for antibiotic
treatment of urinary tract infections (UTI) due to cystitis or
pyelonephritis versus respiratory tract infections due to
VAT and VAP (Figure 1A). Patients with UTI presenting
with fever, leukocytosis, dysuria, and a urine culture havingLtd. The licensee has exclusive rights to distribute this article, in any medium, for 12
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Figure 1 Pathogenesis and routine antibiotic therapy for urinary tract infections versus ventilator-associated pneumonia and
tracheobronchitis. (A) The pathogenesis of ‘ascending’ urinary tract infection due to cystitis or pyelonephritis or both, which are currently
treated with antibiotics as a ‘standard of care’. (B) The pathogenesis of ‘descending’, primarily ‘one-way’ respiratory tract infection manifests as
ventilator-associated tracheobronchitis or pneumonia, for which we would recommend treatment with intravenous or aerosolized antibiotic
therapy or both. Reprinted with permission from Lippincott Williams & Wilkins [12].
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cystitis or pyelonephritis are treated with antibiotics as a
standard of care and infected urine can be removed by
voiding or bladder catheter. By comparison, VAT and VAP
are ‘descending’ infections in a mechanically ventilated,
intubated patient requiring removal of infected secretions
by intermittent suctioning (Figure 1B). Leakage of oropha-
ryngeal secretions around the endotracheal tube (ETT) or
embolization of bacterial biofilm from the inner surface of
the ETT to lower tracheobronchial and alveoli after airway
instrumentation have been implicated in the pathogenesis
of VAT to VAP. Also, bacterial colonization in ventilator
tubing condensate can be inadvertently washed into the
lung, especially with supine positioning. Intubated patients
have decreased bacterial clearance due to reduced cough,
sedation, and the presence of the ETT, all of which may in-
crease bacterial lung burden and challenge lung cellular
and humoral defenses. These significant clinical differences
in pathogenesis between lung and urinary tract infections,
in our opinion, add support for the use of pre-emptive ap-
propriate intravenous or aerosolized antibiotic treatment
(or both) for VAT or VAP as a standard of care [1,8,9].
Ventilated ICU patients developing VAT or VAP or both
are at increased risk for chronic co-morbidities that include
debility, tracheostomy, acute and chronic lung damage, de-
lirium, post-traumatic stress disorder, and short- or long-
term cognitive impairment that increase the need for
rehabilitation, chronic care, hospital readmission, and in-
creased health-care costs [13,14]. Unroe and colleagues
[15] studied 99 ventilated patient survivors 1 year after hos-
pital discharge and found increased need for chronic care,
hospital readmission, multiple transitions of care, and in-
creased health-care costs. At 1 year, only 9% of studypatients were living independently, there were 150 hospital
readmissions and numerous transitions to and from
chronic care facilities, and health-care costs were estimated
at $3.5 million per survivor.
In a recent survey of VAT involving medical staff in 288
ICUs in 16 different countries worldwide, 50.3% of re-
spondents recommended antibiotic therapy for VAT, 93%
thought VAT increased length of ICU stay, and 50% be-
lieved that VAT increased patient mortality [16]. Data
from several randomized clinical trials and a meta-analysis
support the use of pre-emptive appropriate antibiotic ther-
apy for VAT to reduce progression to VAP, ventilator days,
length of ICU stay, and associated health-care costs
[3,4,6,8]. Assessing serial semi-quantitative ETA or quanti-
tative ETA cultures allows identification of likely bacterial
pathogens and antibiotic sensitivity data needed to initiate
appropriate ‘targeted’ intravenous or aerosolized antibiotic
therapy (or both), especially for infections due to S. aur-
eus, P. aeruginosa, Acinetobacter species, or other multi-
drug-resistant Gram-negative pathogens [17]. Considering
the available data, we recommend that pre-emptive appro-
priate antibiotic therapy for VAT be considered a new
standard of care.
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